When will China roll out a COVID-19 vaccine? Which countries will get it? | SupChina

“Four vaccines developed by Chinese companies have moved on to Phase 3 trials, accounting for half of the global candidates at that final stage of human testing before approval.”

Read the full article @ SupChina:

China’s CNBG, Sinovac find more countries to test coronavirus vaccines | Reuters

“China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday they have each found two more countries to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.

Serbia and Pakistan have agreed to participate in the Phase 3 trials of CNBG’s vaccine candidates while Sinovac has received approval from Turkey and Bangladesh. The two companies are seeking more data from overseas as new cases in China are dwindling.”

Read the full article @ Reuters:

Swift Covid-19 vaccine within reach, say Swiss scientists | Swissinfo

“A team of researchers at the University of Bern is hoping to be the first to produce a vaccine against Covid-19 and inoculate the entire Swiss population in October.

“We have a realistic chance of being successful,” said Martin Bachmann, head of immunology at the Swiss university via a web conference with ACANU, the United Nations press association. “Switzerland has a history of being pragmatic and is more interested in finding a compromise to get the vaccine faster.”

Since the beginning of the coronavirus outbreak and its designation by the World Health Organization as a Public Health Emergency of International Concern (PHEIC) at the end of January, most international health experts and authorities have said a vaccine should not be expected for about a year to 18 months – at the earliest.”

Read the full article @ Swissinfo:

Coronavirus attacks lining of blood vessels all over the body, Swiss study finds | SCMP

“Researcher says virus enters ‘defence line’ and causes circulation problems, which can lead to multiple organ failure. In addition to a vaccine, he suggests strengthening vascular health may be key to tackling Covid-19.”

Research initiatives to fight COVID-19 | EPFL

“The EPFL COVID-19 academic committee has given the green light to a dozen research projects directly addressing the COVID-19 crisis. In their research, teams from all the Schools work on priority aspects of the pandemic: preventing or tracking contagion, cure and vaccines, diagnostics and testing, and policy and data. Several teams are working together with partner institutions in Switzerland.”

Read the full information @ EPFL:

Wang Yi held separate telephone conversations with the Foreign Minister of Bangladesh, the Swiss Federal Councillor and Foreign Minister | People’s Daily

“On April 7, State Councilor and Foreign Minister Wang Yi held a telephone conversation with Swiss Federal Councillor and Foreign Minister Cassis.

Wang Yi said that China is doing everything in its power to provide support to countries around the world in the fight against epidemics, and has established a green channel to ensure the rapid and convenient delivery of anti-epidemic materials. Switzerland and other countries are suppliers of important components for ventilators, hoping to increase their supply substantially, help enterprises increase production, and alleviate the urgency of countries. This can not only provide material security for the global anti-epidemic struggle, but also help maintain the stability of the global industrial chain and supply chain. The Chinese side is also willing to strengthen cooperation in the research and development of medicines and vaccines with the Swiss side.

Cassis said that Switzerland is willing to strengthen cooperation with China in ventilator production, drug and vaccine research and development, and jointly ensure the stability of the industrial chain and supply chain to reduce the impact of the epidemic on the economic and trade cooperation between the two countries.”

Read the full article @ People’s Daily:

Search for coronavirus vaccine turns spotlight on German biotech firms | Deutsche Welle

“”An der Goldgrube 12″ — literally translated “At the Goldmine 12” in English — is the postal address of German biotech firm Biontech in Mainz, Germany. The name is apt because the company could indeed strike it rich if it succeeds in its newest undertaking: finding a vaccine against coronavirus and the lung disease COVID-19 it causes.

So far, Biontech has been developing drugs against cancer, but a recent cash injection from Chinese drugmaker Fosun Pharma would allow it to speed up its efforts in the global race to find a vaccine against the novel pathogen, Biontech announced Monday (March 17). The Chinese offered €120 million ($133.3 million), some €44 million of the sum are in exchange for shares in Biontech.”

Read the full article @ Deutsche Welle: